Literature DB >> 11491496

Circulating levels of Th1/Th2 cytokines in patients with primary Sjögren's syndrome: correlation with clinical and immunological features.

M Garcíc-Carrasco1, J Font, X Filella, R Cervera, M Ramos-Casals, A Sisó, A Aymamí, A M Ballesta, M Ingelmo.   

Abstract

OBJECTIVE: To analyse the circulating levels of Th1 and Th2 cytokines in patients with primary Sjögren's syndrome (SS), as well as to investigate their association with clinical and immunological manifestations.
METHODS: We included 62 consecutive patients (58 women and 4 men) seen in our Unit. All patients fulfilled 4 or more of the European diagnostic criteria for SS. Serum levels of IL-6 (pg/mL), IL-2 (pg/mL), srIL-2 (pM), TNFalpha (pg/mL) and IL-10 (pg/mL) were determined using a solid phase enzyme immunoassav performed on microtiter plate.
RESULTS: When compared with the control group, high levels of Th1 (11-2, srIL-2) and Th2 (IL-6, IL-10) cytokines were detected in SS patients, although only IL-6 levels reached statistical significance. On the other hand, analysis of the mean serum concentrations of cytokines showed distinct patterns of elevated cytokines according to the organ involved, and elevated levels of IL-6 (126.5 v 20.6 pg/mL, p < 0.05) and IL-10 (10.6 v 2.2 pg/mL, p < 0.005) were observed in those patients with liver involvement. Analysis of the cytokine levels according to the presence of immunological features showed: higher levels of srIL-2 (95.6 v 54.0 pM, p < 0.05) in patients with anti-Ro/SS-A antibodies; increased levels of srIL-2 (111.4 v 59.4 pM, p < 0.05) in patients with antiLa/SS-B antibodies; higher levels of srIL-2 (90.4 vs 50.8 pM, p < 0.05) and TNFalpha (37.9 v 22.6 pg/mL, p = 0.001) in patients with RF and higher levels of IL-6 (88.0 v 23.1 pg/mL, p < 0.05) in patients with cryoglobulins and in those with hypocomplementemia (130.3 vs 21.0 pg/mL, p < 0.05).
CONCLUSION: We found a significant elevation of several circulating cytokines in some clinical and immunological subsets of patients with primary SS. These cytokine patterns may be markers for specific extraglandular involvement in SS and could be of interest in assessing the response to treatment protocols or in monitoring the disease evolution.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11491496

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  20 in total

Review 1.  Experience with experimental biological treatment and local gene therapy in Sjogren's syndrome: implications for exocrine pathogenesis and treatment.

Authors:  B M Lodde; B J Baum; P P Tak; G Illei
Journal:  Ann Rheum Dis       Date:  2006-07-31       Impact factor: 19.103

Review 2.  T lymphocytes in Sjögren's syndrome: contributors to and regulators of pathophysiology.

Authors:  Gikas E Katsifis; Niki M Moutsopoulos; Sharon M Wahl
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

Review 3.  Is it Sjögren's syndrome or burning mouth syndrome? Distinct pathoses with similar oral symptoms.

Authors:  Hawra Aljanobi; Amarpreet Sabharwal; Bralavan Krishnakumar; Jill M Kramer
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2017-01-24

Review 4.  Cytokine Milieu in Undifferentiated Connective Tissue Disease: a Comprehensive Review.

Authors:  Britt Nakken; Edit Bodolay; Peter Szodoray
Journal:  Clin Rev Allergy Immunol       Date:  2015-10       Impact factor: 8.667

5.  Th2 cytokine genotypes are associated with a milder form of primary Sjogren's syndrome.

Authors:  M Pertovaara; J Antonen; M Hurme
Journal:  Ann Rheum Dis       Date:  2005-09-15       Impact factor: 19.103

6.  Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren's syndrome.

Authors:  B M Lodde; F Mineshiba; J Wang; A P Cotrim; S Afione; P P Tak; B J Baum
Journal:  Ann Rheum Dis       Date:  2005-06-23       Impact factor: 19.103

7.  Relationship between serum levels of IL-18 and IgG1 in patients with primary Sjögren's syndrome, rheumatoid arthritis and healthy controls.

Authors:  P Eriksson; C Andersson; C Ekerfelt; J Ernerudh; T Skogh
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

Review 8.  Cytokines in Sjögren's syndrome.

Authors:  N Roescher; P P Tak; G G Illei
Journal:  Oral Dis       Date:  2009-06-10       Impact factor: 3.511

9.  Aspirin-Triggered Resolvin D1 Versus Dexamethasone in the Treatment of Sjögren's Syndrome-Like NOD/ShiLtJ Mice - A Pilot Study.

Authors:  Justin T Easley; Joel W Nelson; Rachel E Mellas; Salah Sommakia; Chunhua Wu; Bryan Trump; Olga J Baker
Journal:  J Rheum Dis Treat       Date:  2015-12-17

10.  Anti-inflammatory effect of peroxisome proliferator-activated receptor-γ (PPAR-γ) on non-obese diabetic mice with Sjogren's syndrome.

Authors:  Xiaomei Li; Bei Xu; Yiping Wang; Li Wei
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.